EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

14TEAD Inhibition by IAG933 as a Novel Therapeutic Strategy for Cholangiocarcinoma

Hidemi Nishi, Erik Jessen, Brandon A Wilbanks, Danielle M Carlson, Amro M Abdelrahman, Enis H Ozmert, J Pedro F Safi, Shelby K Yee, Emily L Siegler, Jack W Sample, Nathan W Werneburg, Rory L Smoot

The Oncologist · 01.06.2026 · 31 (Supplement_1)

DOI: 10.1093/oncolo/oyag205.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 23.06.2026. Verfasst von Hidemi Nishi und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cholangiocarcinoma (CCA) is an aggressive hepatobiliary malignancy with marked molecular heterogeneity, limited systemic treatment options, and poor prognosis. Chemoresistance and KRAS mutations remain major therapeutic challenges. Dysregulation of the Hippo pathway, particularly YAP/TAZ hyperactivation, drives CCA progression and resistance. TEAD, the essential transcriptional partner of YAP/TAZ, represents a promising target. IAG933 is a novel oral pan-TEAD inhibitor designed to disrupt YAP/TAZ–TEAD interactions. RMC-6236, a pan-KRAS inhibitor, has also gained attention. Combining TEAD and KRAS inhibition may overcome resistance and improve efficacy in CCA.

Methods

We evaluated IAG933 in human (HuCCT1, RBE) and murine (SB1, FAC) CCA cell lines. Cells were treated with IAG933 alone or in combination with GemCis or RMC-6236. Cell viability assays were used to determine IC50 values and calculate combination index (CI). TEAD activity was assessed by luciferase reporter and qRT-PCR of YAP/TAZ target genes (CTGF, CYR61, NUAK2). In vivo efficacy was evaluated in syngeneic orthotopic and patient-derived xenograft (PDX) models.

Results

IAG933 suppressed TEAD-dependent transcription (IC50≈500 nM) and downregulated YAP/TAZ target genes. Combination with GemCis or RMC-6236 produced synergistic effects (CI < 1) in all CCA lines. In vivo, IAG933 monotherapy suppressed tumor growth similarly to GemCis. Dual TEAD and KRAS inhibition achieved marked tumor regression and significantly delayed tumor regrowth after treatment cessation in KRAS-mutant PDX models.

Conclusion

IAG933 effectively suppresses YAP/TAZ–TEAD signaling and inhibits CCA growth. While the combination with GemCis showed limited additional benefit due to strong single-agent efficacy, synergy with RMC-6236 produced durable antitumor effects, particularly in run-out studies, delaying regrowth in KRAS-mutant models. These findings highlight IAG933 as a promising therapeutic candidate targeting the Hippo–TEAD pathway, with potential benefit in KRAS-mutant CCA.

Zitieren

APA

Nishi, H., Jessen, E., Wilbanks, B. A., Carlson, D. M., Abdelrahman, A. M., Ozmert, E. H., Safi, J. P. F., Yee, S. K., Siegler, E. L., Sample, J. W., Werneburg, N. W., & Smoot, R. L. (2026). 14TEAD Inhibition by IAG933 as a Novel Therapeutic Strategy for Cholangiocarcinoma. The Oncologist, 31(Supplement_1). https://doi.org/10.1093/oncolo/oyag205.015

Vancouver

Nishi H, Jessen E, Wilbanks BA, Carlson DM, Abdelrahman AM, Ozmert EH, et al. 14TEAD Inhibition by IAG933 as a Novel Therapeutic Strategy for Cholangiocarcinoma. The Oncologist. 2026;31(Supplement_1). doi:10.1093/oncolo/oyag205.015

BibTeX
@article{Nishi2026,
  author = {Nishi, Hidemi and Jessen, Erik and Wilbanks, Brandon A and Carlson, Danielle M and Abdelrahman, Amro M and Ozmert, Enis H and Safi, J Pedro F and Yee, Shelby K and Siegler, Emily L and Sample, Jack W and Werneburg, Nathan W and Smoot, Rory L},
  title = {14TEAD Inhibition by IAG933 as a Novel Therapeutic Strategy for Cholangiocarcinoma},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {Supplement_1},
  doi = {10.1093/oncolo/oyag205.015}
}
Kostenlos starten →